Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues. "This has been an exceptional first half for Vertex on all fronts and most importantly, in our efforts to bring our CF medicines to more people around the world.

Vertex Reports Second-Quarter 2020 Financial Results

Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players

Vertex Pharmaceuticals For A Strong Portfolio

BioMarin Pharmaceutical

Illumina

The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.

3 Unstoppable Stocks to Buy Before the Next Market Crash

IBD 50 and Sector Leaders member Vertex Pharmaceuticals is expected to report earnings on Jul. 30. It's trading now trading 6% below the 295.65 buy point from a second-stage flat.

Stocks To Watch With Next Quarterly Report On Tap: Vertex Pharmaceuticals

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.

Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?

Amgen

Eli Lilly

Regeneron Pharmaceuticals

Seagen

Zoetis

The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.

Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks

BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and one gating mutation (F/G) or one copy of the F508del mutation and one residual function mutation (F/RF). The study met its primary endpoint of mean absolute within-group change in percent predicted forced

Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

Vertex Inc. VERX, set terms for its initial public offering on Monday, with plans to offer 21.2 million shares priced at $14 to $16 each.

Tax software company Vertex to offer 21.2 million shares in planned IPO, priced at $14 to $16 each

Which stock wins in a battle of two big biotechs?

Better Buy: Vertex Pharmaceuticals vs. Regeneron

BOSTON, July 16, 2020 /PRNewswire/ -- TRIA, a principal-led architecture firm with a focus on designing unique workspaces for science, technology, and corporate clients, announced today that it is designing a new cell and genetic therapies research site in the Boston area for Vertex.

Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research Site

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m.

Vertex to Announce Second-Quarter 2020 Financial Results on July 30

Brookfield Infrastructure Partners L.P.

Dollar General

Be prepared for the next market downturn with these great stocks.

3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again

Corcept Therapeutics

QuidelOrtho Corp

Veeva Systems

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.40, moving -0.18% from the previous trading session.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know

Alexion Pharma

Galapagos

Novo Nordisk

In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital.

5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared first on Investor's Business Daily.

These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why

Emergent BioSolutions

Exelixis

Genmab - ADR

These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.

5 Booming Biotech Stocks to Buy

DexCom

Teladoc

West Pharmaceutical Services

Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.
The post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.

Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones

Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?

Better Buy: Vertex Pharmaceuticals vs. Galapagos

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its reimbursement agreement with NHS England for Vertex’s cystic fibrosis medicines to include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with KALYDECO® (ivacaftor) 150 mg, ahead of the medicine’s anticipated approval by the European Commission. The new expanded agreement includes reimbursed access to Vertex’s currently licensed medicines — KALYDECO® (ivaca

Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).

Can Vertex (VRTX) Stock Continue to Grow Earnings?

Elements from the past, present, and future are reasons to be optimistic about this biotech star.

3 Reasons Why Vertex Is a Great Stock to Buy and Hold for the Long Term

Is  (VRTX) Outperforming Other Medical Stocks This Year?

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.

News for Vertex Pharmaceuticals Stock (VRTX)